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Thrombosis
Annexin V C/T-1 polymorphism and pregnancy
complications
The –1T variant of the annexin V gene, which has
been suggested to have a protective role against
thrombotic disease, was evaluated in 140 women
with pregnancy complications and 317 control
women with uncomplicated pregnancies. The pres-
ence of the -1 CT or TT genotype did not show a
protective effect in normal pregnancies.Haematologica 2006; 91:864
(http://www.haematologica.org/journal/2006/06/864.html)
Pregnancy complications such as intrauterine growth
restriction (IUGR), pre-eclampsia, abruptio placentae and
late fetal loss are often associated with abnormal placental
development and disturbances of hemostasis leading to
inadequate placental perfusion. The human placental syn-
cytiotrophoblast is a rich source of annexin  V, a protein
that displays a strong in vitro anticoagulant activity due to
its  high affinity binding to negatively charged phospho-
lipids and to its capacity to displace coagulation factors
from phospholipid membranes, creating a protective shield
against procoagulant reactions. The anatomic location of
annexin V on the apical surface of placental villi facing the
maternal slow-moving blood in the intervillous circulation
might, therefore, play an antithrombotic role by inhibiting
intervillous thrombosis and maintaining blood fluidity, so
that nutrition exchange functions in the placenta result
unimpaired. It has been reported that pregnant women
with anti-phospholipid circulating antibodies and recur-
rent placental thromboses show decreased levels of annex-
in V on the placental villi,1 but these data were not con-
firmed by others.2 Recently, a C to T transition has been
described in the Kozak region of the annexin V gene, at
position –1, directly associated with the regulation of
translation.3 The –1T variant  increases translation efficien-
cy, resulting in a 1.4 fold increase in protein production,
suggesting a protective role against thrombotic disease, as
reported in premature myocardial infarction.3 Considering
that annexin V is highly concentrated in the placenta, we
hypothezised that complicated pregnancies such as those
with late fetal loss or IUGR may be associated with a
reduced expression of annexin V (associated with the -1
CC allele).
One hundred and forty-three women with pregnancy
complications (95 with late fetal loss and 48 with IUGR)
and 334 control women with uncomplicated pregnancies
and no history of thromboembolic diseases were investi-
gated. The characteristics of the study population have
been reported elsewhere.4,5 Briefly, late fetal loss was
defined as intrauterine fetal death after 20 weeks of gesta-
tion, according to the WHO. IUGR pregnancies were
defined by the concomitant presence of three characteris-
tics: reduced intrauterine growth; birth weight below the
10th percentile for birth weight and gestational age, and
abnormal Doppler velocimetry of the umbilical artery.
Causes for exclusion were: history of venous thrombosis
or the presence of anti-phospholipid syndrome, uterine or
placental malformations, multiple gestation with late fetal
loss of only one fetus, hydrops or erythroblastosis fetalis,
congenital anomalies or abnormal karyotyping of the
fetus. 
The –1 CT polymorphism of the annexin V gene was
evaluated by polymerase chain reaction amplification and
restriction analysis (using Nco I) in 140 cases and 317 con-
trols. The prevalence of the rare genotype (-1 CT or TT) in
the control group (24%) was similar to that described by
Gonzales-Conejero (22%).3 The presence of the -1 CT or
TT genotype did not show a protective effect in all compli-
cated pregnancies taken together. Nevertheless, when
patients with late fetal loss or IUGR were analyzed sepa-
rately, the prevalence of the –1 CT or TT genotype
appeared significantly different (15% and 35% respective-
ly, p=0.02), suggesting that these pregnancy complications
might have different pathogenetic mechanisms. However
this study did not have sufficient power to analyze late
fetal loss and IUGR separately and observe a 2 fold risk
reduction associated with the –1 CT or TT genotype in the
late fetal loss group. Another drawback of this study is the
lack of data regarding a third group of patients affected by
pre-eclampsia.
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Table 1. Prevalence of the -1 CT annexin V polymorphism in cases
and controls. 
All All LFL Matched LFL IUGR Matched
patients controls patients controls patients IUGR
controls
Annexin V 30/140 75/317 14/94 50/221 16/46 25/96
-1 CT or TT (21%) (24%) (15%) (23%)  (35%) (26%)
Adjusted OR* OR=0.92 OR=0.65 OR=1.45
(95%CI 0.57-1.49) (95%CI 0.34-1.25) (95%CI 0.68-3.10)
*Adjusted for the presence of factor V Leiden and prothrombin G20210A;
LFL: late fetal loss; IUGR: intrauterine growth retardation; OR: odds ratio.
 
